GENELINK INC
10QSB, EX-27, 2000-08-14
MEDICAL LABORATORIES
Previous: GENELINK INC, 10QSB, 2000-08-14
Next: SIMCALA INC, 10-Q, 2000-08-14



<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-END>                               JUN-30-2000
<CASH>                                          39,207
<SECURITIES>                                         0
<RECEIVABLES>                                      100
<ALLOWANCES>                                         0
<INVENTORY>                                     10,615
<CURRENT-ASSETS>                                85,504
<PP&E>                                          68,734
<DEPRECIATION>                                  16,395
<TOTAL-ASSETS>                                 140,882
<CURRENT-LIABILITIES>                          567,611
<BONDS>                                              0
                                0
                                          0
<COMMON>                                     (469,958)
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                   140,882
<SALES>                                         13,536
<TOTAL-REVENUES>                                13,536
<CGS>                                            1,494
<TOTAL-COSTS>                                  352,247
<OTHER-EXPENSES>                               142,785
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              46,558
<INCOME-PRETAX>                              (529,284)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (529,284)
<EPS-BASIC>                                      (.05)
<EPS-DILUTED>                                    (.05)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission